Published in Vaccine Weekly, June 7th, 2000
In this study, published in the Journal of Immunology, investigators used anti-CD3 and anti-CD28 monoclonal antibodies (MAbs) to investigate CD28 expression in CD4+ T cells. "Anti-CD3 alone induced a progressive down-regulation of surface CXCR4 accompanied by a significant decline in the entry of the HXB2 T-cell line-tropic (X4-tropic) HIV-1 clone in CD4+ T cells," P. Secchiero, University of Maryland in Baltimore, and colleagues reported.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly